Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

deutsche homoopathie-union dhu-arzneimittel gmbh & co. kg - atropinum sulfuricum d5 trit., hepar sulfuris d3 trit., kalium bichromicum d4 trit., silicea d2 trit., mercurius bijodatus d8 trit. - tablets - 12,5mg+10mg+50mg+ 5mg+25mg

Egypt - English - EDA (Egyptian Drug Authority)

leurquin - france - injection - 5 mg

Egypt - English - EDA (Egyptian Drug Authority)

amoun pharmaceutical industries co. - injection - 5 mg

Egypt - English - EDA (Egyptian Drug Authority)

amoun pharmaceutical industries co. - injection - 5 mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

mucos emulsionsgesellschaft mbh - pancreatin, trypsin, chymotrypsin, bromelain, papain, amylase, lipase, rutoside trihydrate - tablets gastro-resistant - 300 prot.ua+ 360fip-u+ 300fip-u+ 225fip-u+ 90fip-u+ 50fip-u+ 34fip-u+ 50mg (40/2x20/) and (200/10x20/) in blister, (800) in plas

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

mucos emulsionsgesellschaft mbh - pancreatin, trypsin, chymotrypsin, bromelain, papain, amylase, lipase, rutoside trihydrate - tablets gastro-resistant - 300 prot.ua+ 360fip-u+ 300fip-u+ 225fip-u+ 90fip-u+ 50fip-u+ 34fip-u+ 50mg (40/2x20/) and (200/10x20/) in blister, (800) in plastic container

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

mucos emulsions gmbh - bromelain, trypsin, rutin - tablets gastro-resistant - 450fip-u+ 1440fip-u(24mckat)+ 100mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

heel belgium sa-nv - aconitum napellus d6 18,182 mg/ml; magnesium phosphoricum d6 1 mg/ml; chamomilla d3 0,5 mg/ml; passiflora incarnata d2 0,5 mg/ml; veratrum album d6 1 mg/ml; gelsemium sempervirens d6 1 mg/ml; cuprum sulfuricum d6 0,5 mg/ml; colocynthis d4 1 mg/ml; atropinum sulfuricum d6 1 mg/ml; agaricus muscarius d4 0,5 mg/ml; ammonium bromatum d4 1 mg/ml - solution for injection - aconitum napellus d6 18.182 mg/ml; ammonium bromatum d4 1 mg/ml; atropinum sulphuricum d6 1 mg/ml; colocynthis d4 1 mg/ml; gelsemium sempervirens d6 1 mg/ml; magnesium phosphoricum d6 1 mg/ml; veratrum album d6 1 mg/ml; agaricus muscarius d4 0.5 mg/ml; chamomilla d3 0.5 mg/ml; cuprum sulphuricum d6 0.5 mg/ml; passiflora incarnata d2 0.5 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

bio concepts pty ltd - bromelains, quantity: 100 mg; pancreatin, quantity: 200 mg (equivalent: protease, qty 280 bp unit; equivalent: lipase, qty 4000 bp unit; equivalent: amylase, qty 4800 bp unit); trypsin, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; calcium hydrogen phosphate dihydrate; povidone; hypromellose; magnesium stearate; glucose monohydrate; macrogol 400; maltodextrin - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) nutritional supplement; digestive enzyme formula; contains pancreatic enzymes which are important in maintaining healthy digestive function; bromelain has been shown to have proteolytic activity; synergystic formula of proteolytic enzymes;

Australia - English - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: monobasic sodium phosphate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1-antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.